Single-Blind, Controlled Safety and Immunogenicity Study of Recombinant MVA Virus to Treat HIV Infection

NCT00390078 | Completed Phase 1

• 2 other identifiers: HIV-POL-002NIAID Cont. No. N01-AI-40072
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

At the end of 2004 there were more than 40 million people infected Worldwide with HIV, with an estimated 16,000 new infections every day (UNAIDS, 2004). The HIV epidemic threatens whole societies particularly in Africa and Asia and rates of infections in the Western Countries have also increased over the last few years. However, despite more than 15 years of research, an effective vaccine against HIV and acquired immunodeficiency syndrome (AIDS) has still not been developed. There is considerable evidence that cellular immune responses can effectively control HIV-1 replication during acute and chronic infections thereby possibly protecting individuals from infection and preventing the spread of HIV. To be truly effective in the general population, a vaccine must induce responses specific to immunologically conserved regions. The epitope-based vaccine MVA-mBN32 represent a very logical approach to this problem because its potential to elicit a polyfunctional immune response and to focus these responses to conserved epitopes. In this study the safety, tolerability and immunogenicity of a recombinant MVA-BN® expressing CTL and HTL epitopes of HIV-1 (MVA-mBN32) vs. the vector control MVA-BN® in 30 HIV-infected subjects will be examined. This will include a full analysis of CD4+ T helper cells and CD8+ CTL responses to these epitopes, to establish the potential of such a homologous prime-boost vaccine approach to induce a broad cell-mediated response to different HIV antigens.

Conditions

HIV Infections

Keywords

Vaccine; Safety; T-cell epitope; Acquired Immune Deficiency Syndrome Virus; HIV Therapeutic Vaccine

Outcome Measures

Primary Outcomes (1)

• To compare the safety and reactogenicity of the recombinant MVA-mBN32 expressing functional HIV epitopes and MVA-BN® following repeated vaccination in HIV-1 infected patients

  24 weeks

Study Arms (2)

1

ACTIVE COMPARATOR

20 Subjects, 1x 10E8\_TCID50 MVA-mBN32

Biological: MVA-mBN32

2

PLACEBO COMPARATOR

10 Subjects 1x 10E8\_TCID50 IMVAMUNE

Biological: IMVAMUNE

Interventions

MVA-mBN32 BIOLOGICAL

3 immunizations: 1x 10E8\_TCID50 MVA-mBN32

1

IMVAMUNE BIOLOGICAL

3 immunizations: 1x 10E8\_TCID50 IMVAMUNE

2

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Male or female subjects, aged 18 to 50 years.
• HIV-1 infection.
• Stable on HAART with regard to immunologic and clinical parameters for at least 6 consecutive months prior to study entry.
• Plasma HIV RNA level \< 50 copies/ml for at least 6 months
• Plasma HIV-1 RNA levels of \< 50 copies/ml at study entry.
• CD4 cells above 250/µl.
• CD4 nadir \> 200/µl.
• HLA-A2, HLA-A3 or HLA-B7 positive.
• Laboratory criteria (all of the following must be fulfilled):
• Adequate bone marrow reserve, Adequate renal function, Adequate hepatic function, Cardiac enzymes within normal range
• For women, negative serum pregnancy test at screening and negative urine pregnancy test within 24 hours prior to each vaccination.
• If the volunteer is female and of childbearing potential, she has used adequate contraceptive precautions for 30 days prior to the first vaccination and agrees to use an acceptable method of contraception, and not become pregnant for at least 56 days after the last vaccination.
• Read, signed and dated informed consent document.

You may not qualify if:

• Pregnancy or breast-feeding.
• Uncontrolled serious infection
• History of any serious medical condition, which in the opinion of the investigator, would compromise the safety of the subject.
• History of or active autoimmune disease.
• History of malignancy, other than squamous cell or basal cell skin cancer, unless there has been surgical excision that is considered to have achieved cure.
• History of chronic alcohol abuse (40g / day for at least 6 months) and/or intravenous drug abuse (within the past 6 month).
• History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
• History of anaphylaxis or severe allergic reaction.
• Acute disease (a moderate or severe illness with or without a fever) at the time of enrolment.
• Any continuous therapy that may influence CD4 counts other than anti-retroviral therapy
• Any vaccinations with live vaccines within a period starting 30 days prior to administration of the vaccine and ending 30 days after administration of the study vaccine. Any vaccinations with killed vaccines within a period starting 14 days prior to administration of the study vaccine and ending 14 days after administration of the study vaccine.
• Chronic administration (defined as more than 14 days) of immuno-suppressants or other immune-modifying drugs during a period starting from six months prior to administration of the vaccine and ending at study conclusion.
• Administration or planned administration of immunoglobulins and/or any blood products during a period starting from 3 months prior to administration of the vaccine and ending at study conclusion.
• Prior use of any HIV vaccine or vaccinia immunization within the last 5 years.
• Use of any investigational or non-registered drug or vaccine.

Sponsors & Collaborators

• Bavarian Nordic: lead
• National Institutes of Health (NIH): collaborator

Study Sites (1)

Charité, Campus Virchow-Klinikum

Berlin, 13353, Germany

Location

MeSH Terms

Conditions

HIV Infections; Acquired Immunodeficiency Syndrome

Interventions

smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases; Slow Virus Diseases

Study Officials

• Johannes Hain, PhD

  Bavarian Nordic

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: October 18, 2006
• First Posted: October 19, 2006
• Study Start: January 1, 2007
• Primary Completion: December 1, 2007
• Study Completion: January 1, 2009
• Last Updated: July 10, 2009

Record last verified: 2009-07

Locations

DE (1)